Raman received his Ph.D. in Computational/Theoretical Chemistry from the University of Manchester in 2006. He then took up a postdoctoral positions at Manchester and InhibOx Ltd. conducting research into the structure and function metallo-proteins and addressing the inadequacies of standard computer-aided drug design (CADD) approaches through the application of a range of quantum mechanical and molecular simulation methodologies aimed at modelling non-covalent and covalent interactions drug-protein interactions.
In 2009 he joined LSTM as a senior postdoctoral researcher, where his primary research focus was the design of novel antimalarials through the application and development of structure and ligand-based CADD approaches which incorporated molecular docking, cheminformatics and machine learning techniques. In 2012, he took a position at Unilever PLC within the Maths and Informatics group, designing and deploying mathematical modelling and informatics solutions for a number of biologically focused Home and Personal Care projects. During this time he widened his modelling interests, successfully applying techniques such as PK-PD modelling, response surface modelling and experimental design. In 2013, he re-joined LSTM as PK/PD modeller working on the A-WOL-II drug development project, using PK/PD modelling to optimize dosing strategies for existing and novel anti-microbial therapies for Elephantiasis (Filariasis) and River Blindness (Onchocerciasis).
He is currently project lead on a Wellcome Trust funded Institutional Strategic Seeding Fund project entitled “Early Prediction of the PK of Novel Endoperoxide Antimalarial Chemotherapies: A Cheminformatics Model to Predict Effective Drugs for Multidrug Resistant Plasmodium falciparum”. This project aims to predict preclinical pharmacokinetic parameters from the chemical structure and physicochemical properties of a library of endoperoxides through the application of QSAR/QSPR techniques. This technology platform will enable more accelerated and focused design of endoperoxides that match the optimal target product profile of a once-daily short antimalarial treatment conducive to high patient compliance and high systemic drug exposures which are required to overcome or mitigate against resistance:
More recently he has led PKPD analysis on two clinical trials investigating efficacy and safety of Antimalaria therapies in pregnant women in an African setting and an Ebola therapy in the 2014-2016 Sierra Leone EVD epidemic. These studies were performed in collaboration with investigators from LSHTM and Oxford University/University of Glasgow, respectively. As part of the Hastings modelling group, Raman currently leads work in the on predicting impact and spread of resistance to artemisinin combination therapies (ACTs) using pharmaco-epidemiological modelling methods in collaboration with the Health Systems Research and Dynamical Modeling Unit at the Swiss Tropical Institute of public health (Swiss TPH).